Impact Biomedical IncNYSE American:IBO
- LAST PRICE2.5000
- TODAY'S CHANGE (%)-0.1200 (-4.5802%)
- Bid / Lots2.5000/ 1
- Ask / Lots2.7000/ 1
- Open / Previous Close2.4500 / 2.6200
- Day Range
- 52 Week Range
- Volume12,073
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IBO |
|---|---|---|
| 09:32 ET | 6734 | 2.45 |
| 09:33 ET | 100 | 2.56 |
| 09:35 ET | 1000 | 2.6745 |
| 09:51 ET | 440 | 2.88 |
| 09:53 ET | 290 | 2.88 |
| 10:04 ET | 360 | 2.63 |
| 10:33 ET | 700 | 2.64 |
| 10:54 ET | 600 | 2.59 |
| 11:25 ET | 526 | 2.5 |
Nov 19, 2024
Impact BioMedical Inc. Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision, from 8:00AM ET on Tuesday Nov 19, 2024 by Dow Jones
8:00AM ET on Tuesday Nov 19, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Impact Biomedical Inc | 30.1M | -11.9x | --- |
ALT5 Sigma Corp | 30.2M | -0.6x | --- |
Surrozen Inc | 30.2M | -0.5x | --- |
Chemomab Therapeutics Ltd | 29.6M | -1.6x | --- |
ProMIS Neurosciences Inc | 31.2M | -5.0x | --- |
RenovoRx Inc | 29.0M | -2.3x | --- |
Company Information
Impact Biomedical Inc. is a human healthcare company and is a wholly owned subsidiary of DSS, Inc. The Company, through the utilization of its intellectual property rights, or through investment in, or through acquisition of companies in the bio health and biomedical fields, focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. The Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. The Company, through its subsidiary, Global BioLife, Inc., focuses on research in four main areas: the Linebacker project, which develops a universal therapeutic drug platform; a new sugar substitute called Laetose; a multi-use fragrance called 3F (Functional Fragrance Formulation), which is a mosquito fragrance product; and Equivir/Nemovir, a blend of natural polyphenols designed as an antimicrobial medication.
Contact Information
- Headquarters
- 1400 Broadfield Blvd., Suite 130HOUSTON, TX, United States 77084
- Phone
- 585-232-1500
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Frank Heuszel
- Chief Financial Officer
- Todd Macko
- Chief Operating Officer
- Mark Suseck
- Director
- Elise Brownell
- Director
- Jason Grady
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $30.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 11.5M |
Impact Biomedical Inc does not pay a dividend. | |
Beta | --- |
EPS | $-0.21 |
Book Value | $2.19 |
P/E Ratio | -11.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | 13.6x |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
